Biohaven Pharmaceutical Holding Co Ltd. (BHVN) saw its stock price plummet 6.46% in pre-market trading on Wednesday, as investors reacted negatively to the company's announcement of a proposed public offering of common shares. The sharp decline reflects growing concerns over potential dilution of existing shareholders' stakes.

The pharmaceutical company revealed plans to launch an underwritten public offering of $150 million of its common shares. Additionally, Biohaven stated it would grant underwriters a 30-day option to purchase up to an additional $22.5 million of shares, potentially bringing the total offering to $172.5 million. The company intends to use the net proceeds from this offering for general corporate purposes, though specific details were not provided.

This move by Biohaven to raise capital through a share offering is a common strategy for pharmaceutical companies to fund research, development, and other operational expenses. However, such offerings typically lead to stock price declines as they increase the total number of outstanding shares, thereby diluting the value of existing shares. The market's negative reaction suggests that investors are concerned about the impact of this dilution on their holdings, particularly in light of the company's recent setback when the U.S. FDA declined to approve troriluzole, its experimental drug for spinocerebellar ataxia, earlier this month.